|
1
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhu W, Kato Y and Artemov D: Heterogeneity
of tumor vasculature and antiangiogenic intervention: Insights from
MR angiography and DCE-MRI. PLoS One. 9:e865832014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrara N and Ferrara N: Vascular
endothelial growth factor: Molecular and biological aspects. Curr
Top Microbiol Immunol. 237:1–30. 1999.PubMed/NCBI
|
|
4
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar
|
|
5
|
Zhang D, Li B, Shi J, Zhao L, Zhang X,
Wang C, Hou S, Qian W, Kou G, Wang H, et al: Suppression of tumor
growth and metastasis by simultaneously blocking vascular
endothelial growth factor (VEGF)-A and VEGF-C with a
receptor-immunoglobulin fusion protein. Cancer Res. 70:2495–2503.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen AI and Advani RH: Beyond the
guidelines in the treatment of peripheral T-cell lymphoma: New drug
development. J Natl Compr Canc Netw. 6:428–435. 2008.PubMed/NCBI
|
|
7
|
Tischer E, Mitchell R, Hartman T, Silva M,
Gospodarowicz D, Fiddes JC and Abraham JA: The human gene for
vascular endothelial growth factor. Multiple protein forms are
encoded through alternative exon splicing. J Biol Chem.
266:11947–11954. 1991.PubMed/NCBI
|
|
8
|
Houck KA, Leung DW, Rowland AM, Winer J
and Ferrara N: Dual regulation of vascular endothelial growth
factor bioavailability by genetic and proteolytic mechanisms. J
Biol Chem. 267:26031–26037. 1992.PubMed/NCBI
|
|
9
|
Koutsioumpa M, Poimenidi E, Pantazaka E,
Theodoropoulou C, Skoura A, Megalooikonomou V, Kieffer N, Courty J,
Mizumoto S, Sugahara K, et al: Receptor protein tyrosine
phosphatase beta/zeta is a functional binding partner for vascular
endothelial growth factor. Mol Cancer. 14:19–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oršolić N: Bee venom in cancer therapy.
Cancer Metastasis Rev. 31:173–194. 2012. View Article : Google Scholar
|
|
11
|
Wang C, Chen T, Zhang N, Yang M, Li B, Lü
X, Cao X and Ling C: Melittin, a major component of bee venom,
sensitizes human hepatocellular carcinoma cells to tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
by activating CaMKII-TAK1-JNK/p38 and inhibiting IκBα kinase-NF-κB.
J Biol Chem. 284:3804–3813. 2009. View Article : Google Scholar
|
|
12
|
Gajski G and Garaj-Vrhovac V: Melittin: A
lytic peptide with anti-cancer properties. Environ Toxicol
Pharmacol. 36:697–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu S, Yu M, He Y, Xiao L, Wang F, Song C,
Sun S, Ling C and Xu Z: Melittin prevents liver cancer cell
metastasis through inhibition of the Rac1-dependent pathway.
Hepatology. 47:1964–1973. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hoskin DW and Ramamoorthy A: Studies on
anticancer activities of antimicrobial peptides. Biochim Biophys
Acta. 1778:357–375. 2008. View Article : Google Scholar
|
|
15
|
Soman NR, Baldwin SL, Hu G, Marsh JN,
Lanza GM, Heuser JE, Arbeit JM, Wickline SA and Schlesinger PH:
Molecularly targeted nanocarriers deliver the cytolytic peptide
melittin specifically to tumor cells in mice, reducing tumor
growth. J Clin Invest. 119:2830–2842. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee MT, Chen FY and Huang HW: Molecular
mechanism of Peptide-induced pores in membranes. Biochemistry.
43:3590–3599. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huh JE, Kang JW, Nam D, Baek YH, Choi DY,
Park DS and Lee JD: Melittin suppresses VEGF-A-induced tumor growth
by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway.
J Nat Prod. 75:1922–1929. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shin JM, Jeong YJ, Cho HJ, Park KK, Chung
IK, Lee IK, Kwak JY, Chang HW, Kim CH, Moon SK, et al: Melittin
suppresses HIF-1α/VEGF expression through inhibition of ERK and
mTOR/p70S6K pathway in human cervical carcinoma cells. PLoS One.
8:e693802013. View Article : Google Scholar
|
|
19
|
Pichia Expression Kit Version F. A Manual
of Methods for Expression of Recombinant Proteins in Pichia
pastoris. Invitrogen. 2002
|
|
20
|
Ciomber A, Smagur A, Mitrus I, Cichoń T,
Smolarczyk R, Sochanik A, Szala S and Jarosz M: Antitumor effects
of recombinant antivascular protein ABRaA-VEGF121 combined with
IL-12 gene therapy. Arch Immunol Ther Exp (Warsz). 62:161–168.
2014. View Article : Google Scholar
|
|
21
|
Xu WW, Li B, Lam AK, Tsao SW, Law SY, Chan
KW, Yuan QJ and Cheung AL: Targeting VEGFR1- and VEGFR2-expressing
non-tumor cells is essential for esophageal cancer therapy.
Oncotarget. 6:1790–1805. 2015.PubMed/NCBI
|
|
22
|
Liu M, Zong J, Liu Z, Li L, Zheng X, Wang
B and Sun G: A novel melittin-MhIL-2 fusion protein inhibits the
growth of human ovarian cancer SKOV3 cells in vitro and in vivo
tumor growth. Cancer Immunol Immunother. 62:889–895. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee MT, Sun TL, Hung WC and Huang HW:
Process of inducing pores in membranes by melittin. Proc Natl Acad
Sci USA. 110:14243–14248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sommer A, Fries A, Cornelsen I, Speck N,
Koch-Nolte F, Gimpl G, Andrä J, Bhakdi S and Reiss K: Melittin
modulates keratinocyte function through P2 receptor-dependent ADAM
activation. J Biol Chem. 287:23678–23689. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qu L, Jiang M, Li Z, Pu F, Gong L, Sun L,
Gong R, Ji G and Si J: Inhibitory effect of biosynthetic nanoscale
peptide Melittin on hepatocellular carcinoma, driven by survivin
promoter. J Biomed Nanotechnol. 10:695–706. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jo M, Park MH, Kollipara PS, An BJ, Song
HS, Han SB, Kim JH, Song MJ and Hong JT: Anti-cancer effect of bee
venom toxin and melittin in ovarian cancer cells through induction
of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol
Appl Pharmacol. 258:72–81. 2012. View Article : Google Scholar
|
|
27
|
Liu H, Han Y, Fu H, Liu M, Wu J, Chen X,
Zhang S and Chen Y: Construction and expression of sTRAIL-melittin
combining enhanced anticancer activity with antibacterial activity
in Escherichia coli. Appl Microbiol Biotechnol. 97:2877–2884. 2013.
View Article : Google Scholar
|
|
28
|
Su M, Chang W, Cui M, Lin Y, Wu S and Xu
T: Expression and anticancer activity analysis of recombinant human
uPA1-43-melittin. Int J Oncol. 46:619–626. 2015.
|
|
29
|
Wang DD, Su MM, Sun Y, Huang SL, Wang J
and Yan WQ: Expression, purification and characterization of a
human single-chain Fv antibody fragment fused with the Fc of an
IgG1 targeting a rabies antigen in Pichia pastoris. Protein Expr
Purif. 86:75–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
